An observational study in Osteoarthritis, Avascular Necrosis and Rheumatoid Arthritis, sponsored by Encore Medical, L.P.. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-02-09.
Sponsored by Encore Medical, L.P. · Observational
The purpose of this study is to evaluate the survivorship and efficacy of the Encore CLP® Hip stem in a group of no more than 200 patients from whom data has already been collected.
477 studies on the registry are indexed under Necrosis; 54 are open to participants now.
This study's enrollment of 61 is below the median of 100 across 147 observational studies indexed under Necrosis.
Browse Necrosis studies →Encore Medical, L.P. is the lead sponsor of 21 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Individuals who meet the indications for use of the CLP Hip Stem AND who meet the inclusion/exclusion criteria
Noninflammatory degenerative joint disease including
Exclusion Criteria:
Device: Encore CLP® Hip stem
Subjects with osteoarthritis, rheumatoid arthritis or avascular necrosis of the natural femoral head who have received the Encore CLP® Hip stem and are willing to participate in the study.
The survivorship and efficacy of the Encore CLP® Hip stem
Time frame: 2 year
This study is terminated, as verified in Feb 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Encore Medical, L.P.